ArticleEuropean journal of nuclear medicine and molecular imaging2021
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 48 citations in OpenAlex.
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [European journal of nuclear medicine and molecular imaging · 2026Article
- Optimizing PSMA-617-based inhibitors through charged linker modifications: Insights into structure-activity relationships.Theranostics · 2026Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer.Molecular imaging and biology · 2025Article
- Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass.Annals of nuclear medicine · 2024Article
- Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?Pharmaceuticals (Basel, Switzerland) · 2024Article
- A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [EJNMMI radiopharmacy and chemistry · 2024Article
- PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?Theranostics · 2024Article
- Preclinical Evaluation of a Novel High-Affinity Radioligand [International journal of molecular sciences · 2023Article
- Preclinical Imaging of Prostate Cancer.Seminars in nuclear medicine · 2023Review
- Predicting the effect of different folate doses on [EJNMMI research · 2023Article
- Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer.Molecules (Basel, Switzerland) · 2023Article
- Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.Nuclear medicine and molecular imaging · 2022Review
- Advances in PSMA theranostics.Translational oncology · 2022Article
- Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management.Translational oncology · 2022Article
- Sublingual Atropine Administration as a Tool to Decrease Salivary Glands' PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [Pharmaceutics · 2022Article
- Article
- Two diverse carriers are better than one: A case study in α-particle therapy for prostate specific membrane antigen-expressing prostate cancers.Bioengineering & translational medicine · 2022Article
- A Prostate-Specific Membrane Antigen-Targeted Near-Infrared Conjugate for Identifying Pulmonary Squamous Cell Carcinoma during Resection.Molecular cancer therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
purposePeptide-based prostate-specific membrane antigen (PSMA) targeted radionuclide therapy (TRT) agent [
methodsGroups of athymic nude mice (n = 4) bearing PC3-PIP (PSMA+) tumor xenografts were administered with [
resultsBiodistribution studies at 1 h post-administration revealed that [
conclusionThe uptake of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.